Genzyme Corporation to Push Argument for Campath Value

BOSTON (Reuters) - Genzyme Corp (GENZ.O), which is fighting off a hostile $18.5 billion bid from Sanofi-Aventis SA (SASY.PA), will on Monday take another stab at persuading investors that its experimental multiple sclerosis drug is worth more than Sanofi's projections. Genzyme, a U.S.-based biotech company that makes drugs for rare diseases, maintains that Campath, a drug it is testing for multiple sclerosis, could generate peak annual sales of $3.5 billion.

Back to news